Lyell Wealth Management LP lifted its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 3.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 22,274 shares of the financial services provider’s stock after buying an additional 735 shares during the period. Lyell Wealth Management LP’s holdings in iShares Biotechnology ETF were worth $3,243,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BNP Paribas Financial Markets grew its stake in iShares Biotechnology ETF by 25.7% during the first quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock worth $282,038,000 after purchasing an additional 420,053 shares during the period. Main Management ETF Advisors LLC grew its position in shares of iShares Biotechnology ETF by 2.6% during the 2nd quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock worth $79,451,000 after buying an additional 14,535 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in shares of iShares Biotechnology ETF by 24.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock worth $29,792,000 after buying an additional 42,822 shares during the period. Raymond James & Associates increased its stake in shares of iShares Biotechnology ETF by 4.4% in the 2nd quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock valued at $26,047,000 after acquiring an additional 7,931 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its position in shares of iShares Biotechnology ETF by 9.4% during the 1st quarter. Osaic Holdings Inc. now owns 160,173 shares of the financial services provider’s stock valued at $21,985,000 after acquiring an additional 13,777 shares during the period. 62.45% of the stock is owned by institutional investors and hedge funds.
iShares Biotechnology ETF Price Performance
Shares of NASDAQ IBB opened at $141.51 on Friday. The company’s fifty day simple moving average is $145.56 and its 200 day simple moving average is $139.99. iShares Biotechnology ETF has a 12-month low of $111.83 and a 12-month high of $150.57.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- Do ETFs Pay Dividends? What You Need to Know
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a SEC Filing?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Transportation Stocks Investing
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.